Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15462040 | 0.92 | HDAC3 (0.56) | SMN1; SMN2MAPTLMNAMGLLHDAC3 | |
| SCHEMBL15462020 | 0.89 | LMNA (0.57) | MAPTLMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL1618986 | 0.86 | ALDH1A1 (0.70) | SMN1; SMN2MAPTLMNAHDAC3HDAC4 | |
| SCHEMBL1618669 | 0.85 | ALDH1A1 (0.57) | MAPTLMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL1617589 | 0.85 | L3MBTL1 (0.60) | SMN1; SMN2MAPTLMNAHDAC3HDAC4 | |
| SCHEMBL1618834 | 0.85 | GPR183 (0.55) | SMN1; SMN2MAPTLMNAHDAC3HDAC4 | |
| SCHEMBL1617566 | 0.85 | HDAC3 (0.53) | SMN1; SMN2MAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL1619009 | 0.85 | WDR5 (0.52) | SMN1; SMN2MAPTLMNAKMT2AMEN1 | |
| SCHEMBL1618906 | 0.84 | ALDH1A1 (0.62) | SMN1; SMN2MAPTLMNAHDAC3HDAC4 | |
| SCHEMBL1618665 | 0.83 | ALDH1A1 (0.52) | SMN1; SMN2MAPTLMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865720-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | disclosed |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-06 | — | — | US | disclosed |
| US-8557825-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20120088754-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF VAN (BE) | 2012-04-12 | — | — | US | disclosed |
| US-8097611-B2 | Sulfonyl-derivatives as novel or histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-01-17 | — | — | US | disclosed |
| US-20100240639-A1 | Sulfonyl-Derivatives as Novel or Histone Deacetylase | VAN EMELEN KRISTOF | 2010-09-23 | — | — | US | disclosed |
| US-7709487-B2 | anticancer agents; can be combined with other HDAC inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-04 | — | — | US | disclosed |
| US-7704998-B2 | anticancer agents; catalytic hydrogenation | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | VAN EMELEN KRISTOF | 2008-05-08 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088754-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | SMN1; SMN2 3960/4885MAPT 4071/4885LMNA 946/4885 |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | SMN1; SMN2 3960/4885MAPT 4071/4885LMNA 946/4885 |
| US-20100240639-A1 | Sulfonyl-Derivatives as Novel or Histone Deacetylase | HDAC3, HDAC1, HDAC11 | SMN1; SMN2 3834/4885MAPT 4026/4885LMNA 1445/4885 |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | SMN1; SMN2 3960/4885MAPT 4071/4885LMNA 946/4885 |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | HDAC1, HDAC11, HDAC3 | SMN1; SMN2 4056/4885MAPT 3759/4885LMNA 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.